Author(s):
Manjusha. P. Mhaske, Swarup. G. Salunke, Aditya. A. Yadav
Email(s):
swarupsalunke004@gmail.com
DOI:
10.52711/0975-4377.2025.00030 
Address:
Manjusha. P. Mhaske1, Swarup. G. Salunke2, Aditya. A. Yadav3
1Asst Prof. Department of Pharmaceutics, Pravara Rural College of Pharmacy, Loni, Dist.- Ahemadnagar.
2,3Students of Third Year B. Pharmacy, Pravara Rural College of Pharmacy, Loni, Dist.- Ahemadnagar.
*Corresponding Author
Published In:
Volume - 17,
Issue - 3,
Year - 2025
ABSTRACT:
Pulsatile drug delivery systems (PDDS) are innovative approaches designed to release drugs in a controlled, time-specific manner to match the biological rhythms of the human body. Unlike conventional sustained or controlled-release systems that maintain steady drug levels, Pulsatile drug delivery systems (PDDS) ensure the release of drugs at predetermined intervals, making them particularly useful for diseases influenced by circadian rhythms, such as asthma, arthritis, cardiovascular disorders, and diabetes Pulsatile drug delivery systems (PDDS) can be classified based on various mechanisms, including time-controlled and stimuli-responsive (such as magnetic fields and ultrasound). These systems enhance therapeutic outcomes by increasing drug bioavailability, minimizing adverse effects, and promoting patient compliance. Formulation strategies involve single-unit and multi-unit systems, using hydrogels, osmotic pumps, and pH-sensitive polymers to achieve the desired drug release profile. This review analyzes the principles, classification, formulation technologies, and recent advancements in pulsatile drug delivery systems (PDDS). It also highlights challenges, such as manufacturing complexities, stability issues, and regulatory considerations, that must be addressed for a successful clinical application. The growing demand for personalized medicine and smart drug delivery further underscores the potential of PDDS in further pharmaceutical research and development.
Cite this article:
Manjusha. P. Mhaske, Swarup. G. Salunke, Aditya. A. Yadav. A Review of Pulsatile Drug Delivery Systems. Research Journal of Pharmaceutical Dosage Forms and Technology.2025; 17(3):212-0. doi: 10.52711/0975-4377.2025.00030
Cite(Electronic):
Manjusha. P. Mhaske, Swarup. G. Salunke, Aditya. A. Yadav. A Review of Pulsatile Drug Delivery Systems. Research Journal of Pharmaceutical Dosage Forms and Technology.2025; 17(3):212-0. doi: 10.52711/0975-4377.2025.00030 Available on: https://rjpdft.com/AbstractView.aspx?PID=2025-17-3-8
REFERENCES:
1. Jain D, Raturi R, Jain V, Bansal P, Singh R. Recent technologies in pulsatile drug delivery systems. Biomatter. 2011; 1: 57-65.
2. Pandit V, Kumar A, Ashawat MS, Verma CP, Kumar P. Recent advancement and technological aspects of pulsatile drug delivery system – A laconic review. Curr Drug Targets 2017; 18: 1191-203.
3. Ciancia S, Cafarelli A, Zahoranova A, Menciassi A, Ricotti L. Pulsatile drug delivery system triggered by acoustic radiation force. Front Bioeng Biotechnol. 2020; 8: 317.
4. Zhao M, Xing H, Chen M, Dong D, Wu B. Circadian clock-controlled drug metabolism and transport. Xenobiotica. 2020; 50(5): 495-505.
5. Albadri AA, Abdulbaqi MR, Almajidi YQ. Recent Trends in Chronopharmaceutics, Pulsatile Drug Delivery System. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2019; 19(4): 41-49.
6. Khan Z, Pillay V, Choonara YE, du Toit LC. Drug delivery technologies for chronotherapeutics applications. Pharm Dev Technol, 2009; 14: 602–612.
7. Moore G, Halberg F. Circadian rhythm of gastric acid secretion in men with active duodenal ulcer. Dig Dis Sci, 1986; 1185–1191.
8. Hofstra W, de Weerd A. How to assess circadian rhythm in humans: A review of literature. Epilepsy Behav, 2008; 13: 438-444.
9. Yui N, Okano T, Sakurai Y. Journal of Controlled Release, 22, 1992; 105-116.
10. Miyata T, Asami N, Uragami T. A reversibly antigen-sensitive hydrogel antigen-antibody bindings macromolecules. Nature. 399, 1999; 766-769.
11. Averitt R, Sarkar D, Halas N. Plasmon resonance shifts of Au coated Au2S nanoshells: Insight into multicomponent nanoparticle growth. Phys Rev Lett. 78, 1997; 4217-4220.
12. Shigehiro OHDO. Chronopharmaceutics: Pharmaceutics focused on biological rhythm. Biol Pharm Bull. 33(2), 2010; 159-167.
13. Gohel MC, Sumitra M. Modulation of active pharmaceutical ingredient release from a novel tablet-in-capsule system containing an effervescent blend. Journal of Controlled Release. 79, 2002; 157-164.
14. Miyata T, Asami N, Uragami T. Life chemistry. Nature, 399, 1999; 766-769.
15. Obaidat AA, Park K. Polymeric biomaterials: Medicinal and pharmaceutical applications. Pharm Res. 1996; 13: 989-995.
16. Sudhamni T, Radhakishan M, Mallela D, Ganesan V. Chronotherapeutic floating pulsatile drug delivery: An approach for time-specific and site absorption of drug. Research Journal of Pharmaceutical Technology. 2011; 4(5).
17. Okano T, Yuim N, Yokoyam M, Yoshida R. Advances in polymeric system for drug delivery. Gordon and Breach, Yverdon, Switzerland, 1994.
18. Stacey GL, Keen NT. Plant-microbe interactions. Chapman and Hall, New York, 1996.
19. Okano T, Yuim N, Yokoyam M, Yoshida R. Advances in polymeric system for drug delivery. Gordon and Breach, Yverdon, Switzerland, 1994.
20. R. Langer. Polymer systems for controlled release of macromolecules. In: J. Wei et al., Advances in Chemical Engineering. Academic Press Limited, London, 1994.
21. Charman S, Charman W. Oral modified release delivery systems. In: Modified release drug delivery technology. New York, Marcel Dekker. 2003; 1-11.
22. R Langer, Polymer systems for controlled release of macromolecules, immobilized enzyme medical bioreactors, and tissue engineering. In: J. Wei, J.L. Anderson, K.B. Bischoff et al. Advances in Chemical Engineering. Academic Press Limited, London NW1 7DX, 1994.
23. Mandell GL, Petri WA. Antimicrobial agents: Penicillins, cephalosporins, and other ß-lactam antibiotics. In Goodman and Gilman's The pharmacological basis of therapeutics, Edited by Hardman JG and Limbird LE, McGraw-Hill, New York, 1996; 9th ed: pp. 1073-1101.
24. Stacey GL, Keen NT. Plant-microbe interactions. Chapman and Hall, New York, 1996.
Electronic Journal Articles/ World Wide Web
25. Sharma VK. US5914134, Pulsatile technology, 1999.
26. Pope, David. EU 0246819 B1, Pulsatile drug delivery system, 1987.
27. http://www.authorstream.com/Presentation/abike-sh086-235005-pulsatile-crug-delivery-system-education-ppt-powerpoint/
28. http://www.opana.com/hop/opana-ec/durability
29. Burnside BA, Guo X, Fiske K, Couch RA, Chang RK, Rudnic EM. US6322819, Pulsatile Technology, 1998.
30. Ellinwood Jr., Everett H. US4003379, Implantable Electromechanically Driven Device, 1977.
31. Parcel P, Vishnupad KS, Venkatesh GM. Timed pulsatile drug delivery systems. US Patent 6,627,2231.
32. Gopi Venkatesh. New tools for timed, pulsatile drug delivery. Pharma Formu and Qual, 2005.
33. Ram S Sakhare, Ashish B Roge, RL Bakal, MA Channawar, AV Chandewar. Pulsatile Drug Delivery Systems: Novel Approach on Control Drug Delivery. Research J. Pharm. and Tech. 3(1): Jan. - Mar. 2010; Page 32-38.
34. A Review on Pulsatile Drug Delivery System Dr. D. Rama Brahma Reddy, D. Tejaswi, K. Anand, M. Bhaskar, M. SaiVenkata Reddy, M. Naveen Kumar, M. Narendra.
35. A Review on Novel Approach Pulsatile Drug Delivery System Nayana D. Patil, M.M. Bari, S.D.Barhate.